160 related articles for article (PubMed ID: 32564116)
21. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
[TBL] [Abstract][Full Text] [Related]
22. Association between polymorphisms of ERCC1 and XPD and clinical response to platinum-based chemotherapy in advanced non-small cell lung cancer.
Li F; Sun X; Sun N; Qin S; Cheng H; Feng J; Chen B; Cheng L; Lu Z; Ji J; Zhou Y
Am J Clin Oncol; 2010 Oct; 33(5):489-94. PubMed ID: 20351547
[TBL] [Abstract][Full Text] [Related]
23. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
[TBL] [Abstract][Full Text] [Related]
24. A phase I open-label dose-escalation study of oral BIBF 1120 combined with standard paclitaxel and carboplatin in patients with advanced gynecological malignancies.
du Bois A; Huober J; Stopfer P; Pfisterer J; Wimberger P; Loibl S; Reichardt VL; Harter P
Ann Oncol; 2010 Feb; 21(2):370-375. PubMed ID: 19889612
[TBL] [Abstract][Full Text] [Related]
25. Paclitaxel-induced sensory peripheral neuropathy is associated with an ABCB1 single nucleotide polymorphism and older age in Japanese.
Tanabe Y; Shimizu C; Hamada A; Hashimoto K; Ikeda K; Nishizawa D; Hasegawa J; Shimomura A; Ozaki Y; Tamura N; Yamamoto H; Yunokawa M; Yonemori K; Takano T; Kawabata H; Tamura K; Fujiwara Y
Cancer Chemother Pharmacol; 2017 Jun; 79(6):1179-1186. PubMed ID: 28447211
[TBL] [Abstract][Full Text] [Related]
26. Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
Vergote I; Debruyne P; Kridelka F; Berteloot P; Amant F; Honhon B; Lybaert W; Leunen K; Geldhof K; Verhoeven D; Forget F; Vuylsteke P; D'Hondt L; Huizing M; Van den Bulck H; Laenen A
Gynecol Oncol; 2015 Aug; 138(2):278-84. PubMed ID: 26049123
[TBL] [Abstract][Full Text] [Related]
27. Association of DNA repair gene variants with colorectal cancer: risk, toxicity, and survival.
Salimzadeh H; Lindskog EB; Gustavsson B; Wettergren Y; Ljungman D
BMC Cancer; 2020 May; 20(1):409. PubMed ID: 32397974
[TBL] [Abstract][Full Text] [Related]
28. Adverse affects of paclitaxel and carboplatin combination chemotherapy in epithelial gynecologic cancer.
Kietpeerakool C; Suprasert P; Srisomboon J
J Med Assoc Thai; 2005 Mar; 88(3):301-6. PubMed ID: 15962635
[TBL] [Abstract][Full Text] [Related]
29. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
[TBL] [Abstract][Full Text] [Related]
30. Prediction of response to chemotherapy by ERCC1 immunohistochemistry and ERCC1 polymorphism in ovarian cancer.
Steffensen KD; Waldstrøm M; Jeppesen U; Brandslund I; Jakobsen A
Int J Gynecol Cancer; 2008; 18(4):702-10. PubMed ID: 17961161
[TBL] [Abstract][Full Text] [Related]
31. Chemotherapy toxicity in gynecologic cancer patients with a body surface area (BSA)>2 m2.
Schwartz J; Toste B; Dizon DS
Gynecol Oncol; 2009 Jul; 114(1):53-6. PubMed ID: 19359030
[TBL] [Abstract][Full Text] [Related]
32. Pharmacogenetic predictors of toxicity to platinum based chemotherapy in non-small cell lung cancer patients.
Pérez-Ramírez C; Cañadas-Garre M; Alnatsha A; Villar E; Delgado JR; Faus-Dáder MJ; Calleja-Hernández MŸ
Pharmacol Res; 2016 Sep; 111():877-884. PubMed ID: 27498158
[TBL] [Abstract][Full Text] [Related]
33. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer.
Ikeda S; Takabe K; Suzuki K
Pathol Int; 2009 Dec; 59(12):863-7. PubMed ID: 20021611
[TBL] [Abstract][Full Text] [Related]
34. Side effects after docetaxel treatment in Taiwanese breast cancer patients with CYP3A4, CYP3A5, and ABCB1 gene polymorphisms.
Tsai SM; Lin CY; Wu SH; Hou LA; Ma H; Tsai LY; Hou MF
Clin Chim Acta; 2009 Jun; 404(2):160-5. PubMed ID: 19332043
[TBL] [Abstract][Full Text] [Related]
35. ERCC1 Expression Can Predict Response to Platinum-Based Induction Chemotherapy in Head and Neck Cancer Cases.
Ameri A; Mortazavi N; Khoshbakht Ahmadi H; Novin K
Asian Pac J Cancer Prev; 2016; 17(S3):87-91. PubMed ID: 27165214
[TBL] [Abstract][Full Text] [Related]
36. Toxicity and therapy outcome associations in LIG3, SLCO1B3, ABCB1, OPRM1 and GSTP1 in high-grade serous ovarian cancer.
Deng F; Laasik M; Salminen L; Lapatto L; Huhtinen K; Li Y; Hautaniemi S; Hynninen J; Niemi M; Lehtonen R
Basic Clin Pharmacol Toxicol; 2023 Jun; 132(6):521-531. PubMed ID: 36988399
[TBL] [Abstract][Full Text] [Related]
37. Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.
Lambrechts S; Lambrechts D; Despierre E; Van Nieuwenhuysen E; Smeets D; Debruyne PR; Renard V; Vroman P; Luyten D; Neven P; Amant F; Leunen K; Vergote I;
BMC Pharmacol Toxicol; 2015 Feb; 16():2. PubMed ID: 25881102
[TBL] [Abstract][Full Text] [Related]
38. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
39. Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin.
Yahata H; Kobayashi H; Sonoda K; Shimokawa M; Ohgami T; Saito T; Ogawa S; Sakai K; Ichinoe A; Ueoka Y; Hasuo Y; Nishida M; Masuda S; Kato K
Int J Clin Oncol; 2016 Jun; 21(3):491-7. PubMed ID: 26662632
[TBL] [Abstract][Full Text] [Related]
40. Promoter polymorphisms of TOP2A and ERCC1 genes as predictive factors for chemotherapy in non-small cell lung cancer patients.
Grenda A; Błach J; Szczyrek M; Krawczyk P; Nicoś M; Kuźnar Kamińska B; Jakimiec M; Balicka G; Chmielewska I; Batura-Gabryel H; Sawicki M; Milanowski J
Cancer Med; 2020 Jan; 9(2):605-614. PubMed ID: 31797573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
